Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lenvatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.94 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 0.94 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.94 |
| ▸ | FGFR4 | P22455 | 12/20 | 0.94 |
| ▸ | RET | P07949 | 6/20 | 0.94 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.94 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.94 |
| ▸ | KIT | P10721 | 3/20 | 0.94 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.94 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.94 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.94 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.94 |
| ▸ | STK10 | O94804 | 2/20 | 0.94 |
| ▸ | ABL1 | P00519 | 2/20 | 0.94 |
| ▸ | BCR | P11274 | 2/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.94 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.94 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.94 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenvatinib SCHEMBL29357626 | 1.00 | FGFR4 (0.94) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL865174 | 1.00 | FGFR4 (0.94) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL3928020 | 0.97 | FGFR4 (0.91) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL864638 | 0.97 | FGFR4 (1.00) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL29349806 | 0.97 | FGFR4 (1.00) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL29372021 | 0.97 | FGFR4 (1.00) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL1389214 | 0.96 | FGFR4 (0.98) | FGFR4RETKDRFGFR1PDGFRB | |
| SCHEMBL28586143 | 0.92 | FGFR4 (0.91) | FGFR4RETKDRFGFR1PDGFRB | |
| SCHEMBL1248140 | 0.90 | FGFR4 (0.87) | FGFR4RETKDRFGFR1PDGFRB | |
| SCHEMBL1894913 | 0.89 | FGFR4 (0.86) | FGFR4RETKDRFGFR1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731793-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731792-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731199-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4727534-A1 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING BREAST CANCER | Burzynski, Stanislaw R. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024263801-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING OVARIAN CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263963-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING HEAD AND NECK CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263972-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING UNCOMMON CANCERS | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263960-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263643-A1 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING BREAST CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263804-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING KIDNEY CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-116650437-A | Lenvatinib mesylate capsule and preparation method thereof | 山东鲁抗医药股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116354880-A | Preparation process of lenvatinib mesylate crystal form C | 南京科默生物医药有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-110404079-B | Pharmaceutical composition of quinoline derivative or salt thereof containing no carbonate and low genotoxic impurity content | 北京睿创康泰医药研究院有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-115598160-A | Quantitative detection method for content of crystal form C of raw material drug in varlitinib mesylate capsule | 齐鲁制药有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115572261-A | Method for removing impurities of varlitinib mesylate | 江苏省肿瘤医院 | 2023-01-06 | — | — | CN | disclosed |
| CN-112300280-B | anti-PD-1 antibody and medical application thereof | 正大天晴康方(上海)生物医药科技有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-109824590-B | Preparation method of Lovatinib and salt thereof | 扬子江药业集团有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-112939859-B | Preparation method of M crystal form of varlitinib mesylate | 南京方生和医药科技有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022022367-A1 | METHOD FOR PREPARING HIGH-PURITY CRYSTAL | 药源药物化学（上海）有限公司 | 2022-02-03 | — | — | WO | disclosed |
| CN-113999173-A | Preparation method of high-purity crystal | 药源药物化学（上海）有限公司 | 2022-02-01 | — | — | CN | disclosed |